Tras 72 semanas de tratamiento con el frmaco dual, se redujo el peso casi un 20%: prdida de peso del 18,4% con tirzepatida vs aumento del 2,5% con placebo, alcanzando la significacin estadstica
In other words: Its a commitment
However, switching medications should always be done under medical supervision to avoid side effects or dosing issues
Medications with a narrow therapeutic index or those requiring rapid onset of action may be particularly affected
References Andreadis, P., Karagiannis, T., Malandris, K., et al
Research suggests it may increase endogenous GLP-1 secretion from intestinal L-cells, providing a mild GLP-1 boosting effect that complements rather than replaces exogenous GLP-1 therapy